Skip to main content
SpringerLink
Log in

Pharmaka mit Wirkung auf die Blutgerinnung

  • Chapter
Pharmakologie und Toxikologie

Part of the book series: Springer-Lehrbuch ((SLB))

  • 852 Accesses

Zusammenfassung

Die Fähigkeit des Organismus zum — mitunter lebensrettenden — Verschluß verletzter Blutgefäße, Hämostase genannt, beruht auf einem Zusammenspiel von Gefäßwand, Thrombozyten und plasmatischem Gerinnungs- und Fibrinolysesystem, als dessen Folge ein sich bildender Fibrinpfropf das kontrahierte Gefäß vorläufig verschließt. Intravasal laufen ständig Gerinnungs- und Fibrinolysevor-gänge ab, die die Bildung und den Abbau von Fibrin in einem physiologischen Gleichgewicht halten. Bei pathologischen Veränderungen kann jedoch verstärkt eine intravasale Gerinnung mit Thrombenbildung oder eine gesteigerte Fibrinolyse mit Blutungsneigung auftreten.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 149.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Adgey AA (1998) An overview of the results of clinical trials with glykoprotein IIb/IIIa inhibitors. Am Heart J 135: S43–55

    Article  Google Scholar 

  • Bartoli F, Lin HK, Ghomashchi F, Gelb MH, Jain MK, Apitz-Castro R (1994) Tight binding inhibitors of 85-kDa phos-pholipase A2 but not 14-kDa phospholipase A2 inhibit rele-ase of free arachidoneate in thrombin-stimulated human platelets. J Biop Chem 269: 15625–15630

    CAS  Google Scholar 

  • Bell WR Jr (1997) Evaluation of thrombolytic agents. Drugs 54 (Suppl 3):11–17

    Article  PubMed  CAS  Google Scholar 

  • Bennett JS (2001) Novel platelet inhibitors. Annu Rev Med 52:161–184

    Article  PubMed  CAS  Google Scholar 

  • Bennett CL, Connors JM, Carwile JM (2000) Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 342:1773–1777

    Article  PubMed  CAS  Google Scholar 

  • Bhatt DL, Topol EJ (2000) Current role of platelet glycopro-tein IIb/IIIa inhibitors in acute coronary syndromes. JAMA 284:1549–1558

    Article  PubMed  CAS  Google Scholar 

  • Blackhart BD, Ruslim-Litrus L, Lu CC, Alves VL, Teng W, Scarborough RM, Reynolds EE, Oksenberg D (2000) Extra-cellular mutations of protease-activated receptor-1 result in differential activation by thrombin and thrombin receptor agonist peptide. Mol Pharmacol 58:1178–1187

    PubMed  CAS  Google Scholar 

  • Bode C, Smalling RW, Berg G (1996) Randomized compari-son of coronary thrombolysis achieved with double-bolus Reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infar-ction. The RAPID II invetigators. Circulation 94: 891–898

    Article  PubMed  CAS  Google Scholar 

  • Carmeliet P, Collen D (1999) New Developments in the mole-cular biology of coagulation and fibrinolysis. In: Antith-rombotics, ed. by Uprichard ACG, Gallagher KP: Handbook of Experimental Pharmacology 132:41–79

    Article  CAS  Google Scholar 

  • Catella-Lawson F (1997) Direct thrombin inhibitors in cardi-ovascular disease. Coron Artery Dis 8:105–111

    Article  PubMed  CAS  Google Scholar 

  • Catella-Lawson F, FitzGerald GA (1999) Therapeutic aspects of platelet pharmacology. In: Antithrombotics, ed. by Uprichard ACG, Gallagher KP: Handbook of Experimental Pharmacology 132:719–734

    Google Scholar 

  • Clarke RJ, Mayo G, Price P, FitzGerald GA (1992) Suppression of thromboxane A2 but not of systemic prostacyclin by con-trolled-release aspirin. N Engl J Med 325:1137–1141

    Article  Google Scholar 

  • Clemetson KJ, Polgar J (1999) Platelet adhesion and aggrega-tion receptors. In: Antithrombotics, ed. by Uprichard ACG, Gallagher KP: Handbook of Experimental Pharmacology 132:155–175

    Google Scholar 

  • Coller BS, Anderson KM, Weisman HF (1996) The anti-GPIIb/IIIa agents: fundamental and clinical aspects. Hae-mostasis 26 (Suppl 4): 285–293

    CAS  Google Scholar 

  • Coughlin SR (2000) Thrombin signalling and protease-activated receptors. Nature 407:258–264

    Article  PubMed  CAS  Google Scholar 

  • Coutrè S, Leung L (1995) Novel antithrombotic therapeutics targeted against platelet glycoprotein IIb/IIIa. Annu Rev Med 46:257–265

    Article  PubMed  Google Scholar 

  • Davis-Bruno KL, Halushka PV (1994) Molecular pharmacology and therapeutic potential of thromboxane A2 receptor antagonists. Adv Drug Res 25:173–202

    CAS  Google Scholar 

  • Domburg van RT, Boersma E, Simoons ML (2000) A review of the long term effects of thrombolytic agents. Drugs 60:293–305

    Article  PubMed  Google Scholar 

  • Doutremepuich C, Seze O de, LeRoy D, Lalanne MC, Anne MC (1990) Aspirin at very ultra low dosage in healthy vo-lunteers:lunteers: Effects on bleeding time, platelet aggregation and coagulation. Haemostasis 20:99–105

    PubMed  CAS  Google Scholar 

  • Esmon CT (1987) The regulation of natural anticoagulant pathways. Science 235–1348–1352

    Google Scholar 

  • Fareed J, Bacher P, Messmore HL (1992) Pharmacological modulation of fibrinolysis by antithrombotic and cardio-vascular drugs. Prog Cardiovasc Dis 34:379–398

    Article  PubMed  CAS  Google Scholar 

  • Fareed J, Lewis BE, Callas DD, Hoppensteadt DA, Walenga JM, Bick RL (1999) Antithrombin agents: the new class of anticoagulant and antithrombotic drugs. Clin Appl Thromb Hemost 5 (Suppl 1): S45–55

    Article  Google Scholar 

  • Ferguson JJ, Waly HM, Wilson JM (1998) Fundamentals of coagulation and glycoprotein IIb/IIIa receptor inhibition. Am Heart J 135:S35–42

    Article  Google Scholar 

  • Fernandes P, Mayer R, MacDonald JL, Cleland AG, Hay-McKay C (2000) Use of danaparoid sodium (Orgaran) as an alternative to heparin sodium during cardiopulmonary bypass: a clinical evaluation of six cases. Perfusion 15:531–539

    Article  PubMed  CAS  Google Scholar 

  • Furie B, Furie CB (1992) Molecular and cellular biology of blood coagulation. N Engl J Med 326:800–806

    Article  PubMed  CAS  Google Scholar 

  • Fuster V, Dyken ML, Vokonas PS, Hennekens C (1993) Aspirin as a therapeutic agent in cardiovascular disease. Circulation 87:659–675

    Article  PubMed  CAS  Google Scholar 

  • Gaede A, Terres W (1999) Therapie des akuten Koronarsyn-droms. ASS, Heparin, LMWH, Hirudin und GP-IIb/IIIa-Blocker. Herz 24: 353–362

    Article  PubMed  CAS  Google Scholar 

  • Gallus AS (1994) Anticoagulants and antiplatelets drugs. Med J Aust 160:78–82

    PubMed  CAS  Google Scholar 

  • Graham FP, Russell DH (1997) Low-molecular-weight heparin: prophylaxis and treatment of venous thromboembo-lism. Annu Rev Med 48:79–91

    Article  Google Scholar 

  • Groos M (1994) Lokal applizierte Acetylsalicylsäure hemmt Thromboxan A2-Bildung. Arzneimitteltherapie 12:121–122

    Google Scholar 

  • Gulba DC (1997) Gerinnungshemmende Substanzen. Herz 21: 12–27

    Google Scholar 

  • Haberl RK, Tiecks FP (1993) Azetylsalizylsäure und Ticlopi-din in der Schlaganfallprophylaxe. Psycho 19:763–768

    Google Scholar 

  • Halushka PV, Pawate S, Martin ML (1999) Thromboxane A2 and other eicosanoids. In: Antithrombotics, ed. by Uprichard ACG, Gallagher KP: Handbook of Experimental Pharmacology 132:459–479

    Google Scholar 

  • Hampton JR, Schroder R, Wilcox RG et al. (1995) Random-ised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial in-farction (INJECT): Trial to investigate equivalence. Lancet 346:329–336

    Article  Google Scholar 

  • Harder S, Thurmann P (1996) Clinically important drug in-teractions with anticoagulants. An update. Clin Pharmaco-kinet 30:416–444

    Article  CAS  Google Scholar 

  • Hedner U (1998) Recombinant activated factor VII as a universal haemostatic agent. Blood Coagul Fibrinolysis 9 (Suppl 1): S147–152

    Google Scholar 

  • Hirsh J, Fuster V (1994) Guide to anticoagulant therapy. 1.Heparin. Circulation 89:1449–1468

    Article  PubMed  CAS  Google Scholar 

  • Hirsh J, Fuster V (1994) Guide to anticoagulant therapy. 2.Oral anticoagulants. Circulation 89:1469–1480

    Article  PubMed  CAS  Google Scholar 

  • Hoyer LW (1994) Hemophilia A. N Engl J Med 330:38–47

    Article  PubMed  CAS  Google Scholar 

  • Hursting MJ, Alford KL, Becker JC, Brooks RL, Joffrion JL, Knappenberger GD, Kogan TP, McKinney AA, Schwarz RP Jr (1997) Novastan (brand of argatroban): a small-mole-cule, direct thrombin inhibitor. Semin Thromb Hemost 23:503–516

    Article  PubMed  CAS  Google Scholar 

  • Jarvis B, Simpson K (2000) Clopidogrel. A review of its use in the prevention of atherothrombosis. Drugs 60: 347–377

    Article  PubMed  CAS  Google Scholar 

  • Johnson PH (1994) Hirudin: Clinical potential of a thrombin inhibitor. Annu Rev Med 45:165–177

    Article  PubMed  CAS  Google Scholar 

  • Keimowitz RM, Pulvermacher G, Mayo G, Fitzgerald DJ (1993) Transdermal modification of platelet function. A dermal aspirin preparation selectively inhibits platelets cyclooxygenase and preserves prostacyclin biosynthesis.Circulation 88:556–561

    Article  PubMed  CAS  Google Scholar 

  • Leblond L, Winocour PD (1999) The coagulation pathway and antithrombotic strategies. In: Antithrombotics, ed. by Uprichard ACG, Gallagher KP: Handbook of Experimental Pharmacology 132:1–39

    Article  CAS  Google Scholar 

  • Lefkovits J, Plow EF, Topol EJ (1995) Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 332:1553–1559

    Article  PubMed  CAS  Google Scholar 

  • Link KP (1959) The discovery of dicumarol and its sequels.Circulation 19:97–107

    Article  PubMed  CAS  Google Scholar 

  • Madan M, Berkowitz SD (1999) Understanding thrombocyto-penia and antigenicity with glycoprotein IIb/IIIa inhibi-tors. Am Heart J 138:317–326

    Article  PubMed  CAS  Google Scholar 

  • Maksimenko AV, Tischenko EG (1999) New thrombolytic strategy: bolus administration of tPA and urokinase-fibri-nogen conjugate. J Thromb Thrombolysis 7:307–312

    Article  PubMed  CAS  Google Scholar 

  • Mannucci PM (2000) Hemostatic drugs. N Engl J Med 339:245–253

    Google Scholar 

  • Markwardt F (1993) Hirudin: The famous anticoagulant agent. Adv Exp Med Biol 340:191–211

    Article  PubMed  CAS  Google Scholar 

  • Menache D, Grossman BJ, Jackson CM (1992) Antithrom-bin III: Physiology, deficiency, and replacement therapy.Transfusion 32:580–588

    Article  PubMed  CAS  Google Scholar 

  • Monreal M, Costa J, Salva P (1996) Pharmacological proper-ties of hirudin and its derivatives. Potential clinical advan-tages over heparin.Drugs Aging 8: 171–182

    Article  PubMed  CAS  Google Scholar 

  • Patrono C (1994) Aspirin as an antiplatelet drug. N Engl J Med 330:1287–1294

    Article  PubMed  CAS  Google Scholar 

  • Pineo GF, Hull RD (1997) Low-molecular-weight heparin: prophylaxis and treatment of venous thromboembolism. Annu Rev Med 48:79–91

    Article  PubMed  CAS  Google Scholar 

  • Rao LV, Ezban M (2000) Active site-blocked activated factor VII as an effective antithrombotic agent: mechanism of ac-tion. Blood Coagul Fibrinolysis 11 (Suppl 1):S135–143

    Article  Google Scholar 

  • Siess W (1997) Platelet receptors: the thrombin receptor. In: Platelets and their factors, ed. by Bruchhausen von F, Walter U. Handbook of Experimental Pharmacology 126:101–154

    Article  CAS  Google Scholar 

  • Suttie JW (1993) Synthesis of vitamin K-dependent proteins. FASEB J 7:445–452

    PubMed  CAS  Google Scholar 

  • Thiagarajan P, Wu KK (1999) Mechanisms of antithrombotic drugs. Adv Pharmacol 46:297–324

    Article  PubMed  CAS  Google Scholar 

  • Turpie AGG, Gent CBM, Laupacis A (1993) A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 329:524–529

    Article  PubMed  CAS  Google Scholar 

  • Vorchheimer DA, Badimon JJ, Fuster V (1999) Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular dis-ease. JAMA 281:1407–1414

    Article  PubMed  CAS  Google Scholar 

  • Walenga JM, Fareed J (1997) Current Status on new anticoagulant and antithrombotic drugs and devices. Curr Opin Pulm Med 3:291–302

    Article  PubMed  CAS  Google Scholar 

  • Warkentin TE (1999) Heparin-induced thrombocytopenia: a ten-year retrospective. Annu Rev Med 50:129–147

    Article  PubMed  CAS  Google Scholar 

  • Weiller C, Diener HC (1993) Ticlopidin - Sekundärprävention des ischämischen Schlaganfalls. Arzneimitteltherapie 11:182–189

    Google Scholar 

  • Weitz JI (1997) Low-molecular-weight heparins. N Engl J Med 337:688–698

    Article  PubMed  CAS  Google Scholar 

  • Weitz JI, Hirsh J (1993) New anticoagulant strategies. J Lab Clin Med 122:364–373

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. C. Taube
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Fachbereich Humanmedizin — Institut für Pharmakologie, Freie Universität Berlin, Thielallee 67-73, 14195, Berlin, Germany

    Eckard Oberdisse

  2. Pharmakologisches Institut, Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg, Germany

    Eberhard Hackenthal

  3. Institut für Pharmakologie und Toxikologie, Universität Marburg/Lahn, Ketzerbach 63, 35032, Marburg, Germany

    Klaus Kuschinsky

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Taube, C. (2002). Pharmaka mit Wirkung auf die Blutgerinnung. In: Oberdisse, E., Hackenthal, E., Kuschinsky, K. (eds) Pharmakologie und Toxikologie. Springer-Lehrbuch. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56314-0_25

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-56314-0_25

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-62634-0

  • Online ISBN: 978-3-642-56314-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation